Enterprise Value
-37.02M
Cash
52.12M
Avg Qtr Burn
-9.57M
Short % of Float
3.24%
Insider Ownership
4.45%
Institutional Own.
39.13%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GB1211 (oral galectin-3 inhibitor) + pembrolizumab (Keytruda®) Details Cancer, Head and neck squamous cell carcinoma, Melanoma | Phase 2 Initiation | |
GB1211 (oral galectin-3 inhibitor) Details Cirrhosis, Non-alcoholic steatohepatitis | Phase 2 Initiation | |
GB2064 (oral LOXL2 inhibitor) Details Fibrosis, Myelofibrosis | Phase 2a Data readout | |
GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details Non-small cell lung carcinoma, Cancer, Fibrosis | Phase 2a Interim update | |
GB0139 (inhaled galectin-3 inhibitor) Details Fibrosis, Pulmonary fibrosis, Lung disease, Idiopathic pulmonary fibrosis | Failed Discontinued |